Recent Updates
Recently added Catalysts

Deramiocel

Phase 3

Muscular Dystrophies | Monoclonal antibody | Rare Disease |Capricor Therapeutics, Inc.|Last Updated: Jun 5, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment106
FDA Designations
ORPHAN_DRUGRMATRARE_PEDIATRIC_DISEASEPRIORITY_REVIEW
Clinical trial landscape

Deramiocel · 2 trials · 9 indications

Phase 3 1Phase 2 1
NCT05126758A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular DystrophyMuscular Dystrophies
ACTIVE NOT_RECRUITING106 Analytics
PHASE3ACTIVE NOT_RECRUITING
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Muscular DystrophiesUnlock trial analytics
Study Endpoints
Primary Endpoints
Change in the upper limb function
At Month 12

Mean percent change from baseline in Performance of the Upper Limb test, version 2 (PUL 2.0) Total Score. Items are scored on a three-point scale: 0=unable to perform the item, 1=impaired or performs with compensation, 2=performs task without compensation. Percent change from baseline is calculated as change from baseline divided by baseline score at the subject level.

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From Baseline Through Month 12
Baseline up to Month 12

Adverse event (AE) is defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE: AE with onset after start of treatment or with onset date before the treatment start date but worsening after the treatment start date. TEAEs included both serious and non-serious TEAEs.

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity From Baseline Through Month 12
Baseline up to Month 12

Severity of adverse events (AE) were assessed by the investigator as Grade 1 = Mild (Transient or mild discomfort; no limitation in activity; no medical intervention/therapy required), Grade 2 = Moderate (Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required), Grade 3 = Severe (Marked limitation in activity, some assistance usually required; medical intervention/therapy required and often requiring hospitalization or prolongation of hospitalization), Grade 4 = Life-threatening (Extreme limitation in activity, significant assistance required; significant medical intervention/therapy required; hospitalization, prolongation of hospitalization, or hospice care) and Grade 5 = Death.

Change From Baseline in Functional Capacity as Assessed by Performance of the Upper Limb Test, Version 2 (PUL 2.0) Total Score.
Baseline, Month 12

PUL 2.0 scale is a 22-item scale used to assess the change that occurs in motor performance of the upper limb overtime from when a participant is still ambulant to the time participant loses all arm function when non-ambulant. PUL 2.0 includes an entry item to define broad starting functional level and 22 items subdivided into shoulder level (six items), mid-level (nine items), and distal level (seven items). Each dimension (shoulder, mid, distal) can be scored separately. There is maximum score of 12 for shoulder level, 17 for mid-level, and 13 for distal level. The total score was calculated by adding three level scores and ranged from 0-42. Higher score indicates better upper limb function.

Secondary Endpoints
Change in cardiac muscle function and structure by assessment of left ventricular ejection fraction
At Month 12
Change in mid-level (elbow) upper limb function
At Month 12
Change in Global Statistical Test (Total GST) combining upper limb function, cardiac muscle function, and patient reported measure of disease severity
At Month 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Deramiocel (CAP-1002)EXPERIMENTALCohort A: Approximatetly 29 subjects will receive deramiocel (CAP-1002A) active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months Cohort B: Approximately 22 participants will receive deramiocel (CAP-1002B) active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months
PlaceboPLACEBO_COMPARATORCohort A: Approximately 29 subjects will receive a Placebo solution via intravenous infusion every 3 months Cohort B: Approximately 22 participants will receive a Placebo solution via intravenous infusion every 3 months
DeramiocelOTHERParticipants will receive an intravenous (IV) infusion of deramiocel (150 million Cardiosphere-Derived Cells (CDCs) per infusion) every 3 months
Interventions
NameTypeDescription
Deramiocel (CAP-1002)BIOLOGICALCohort A: CAP-1002A manufactured in Los Angeles, CA; Cohort B: CAP-1002B manufactured in San Diego, CA
PlaceboBIOLOGICALPlacebo
Unlock Study Design Details
Eligibility Criteria
Age Range10 Years to N/A
SexMALE
Healthy VolunteersNo
Study Sites20

Inclusion Criteria: 1. Male subjects at least 10 years of age at time of consent who are willing and able to provide informed consent to participate in the trial if ≥ 18 years of age or assent with parental or guardian informed consent if \< 18 years of age. If a third-party caregiver is involved, ...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 5, 2026NCT05126758lastUpdatePostDate: changed
LOWJun 5, 2026NCT05126758lastUpdatePostDate: changed
LOWJun 5, 2026NCT05126758lastUpdatePostDate: changed
LOWJun 5, 2026NCT05126758lastUpdatePostDate: changed
LOWMay 26, 2026NCT04428476primaryCompletionDate: changed
LOWMay 26, 2026NCT05126758primaryCompletionDate: changed
LOWMay 24, 2026NCT04428476studyFirstPostDate: changed
LOWMay 24, 2026NCT05126758studyFirstPostDate: changed